Dual effects of the antioxidant agents probucol and carvedilol on proliferative and fatty lesions in hypercholesterolemic rabbits

Atherosclerosis

Volumn 141, Issue 1, 1998, Pages 45-51

  Donetti, E ^a   Soma, M R ^a   Barberi, L ^a   Paoletti, R ^a   Fumagalli, R ^a   Roma, P ^a   Catapano, A L ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Antiatherosclerotic effect; Carvedilol; In vivo model; Probucol

Indexed keywords

ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CARVEDILOL; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PROBUCOL; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; HYPERCHOLESTEROLEMIA; IMAGE ANALYSIS; MALE; MUSCLE GROWTH; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT; VASCULAR SMOOTH MUSCLE;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; AORTA; ARTERIES; ARTERIOSCLEROSIS; CARBAZOLES; CAROTID ARTERIES; CELL DIVISION; HYPERCHOLESTEROLEMIA; MALE; PROBUCOL; PROPANOLAMINES; RABBITS; TUNICA INTIMA; TUNICA MEDIA;

EID: 0032487556     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00146-4     Document Type: Article

References (26)

1. Steinberg D. Lipoproteins and the pathogenesis of atherosclerosis. Circulation. 76:1987;508-514.
2. Holvoet P., Collen D. Oxidized lipoproteins in atherosclerosis and thrombosis. FASEB. J. 8:1994;1279-1284.
3. Steinberg D. Antioxidants and atherosclerosis. A current assessment. Circulation. 84(3):1991;1420-1425.
4. Steinberg D., Parthasarathy S., Carew T.E. In vivo inhibition of foam cell development by probucol in Watanabe rabbits. Am. J. Cardiol. 62:1988;6B-12B.
5. Sasahara M., Raines E.W., Chait A., Carew T.E., Steinberg D., Wahl P.W., Ross R. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. 1. Is the extent of atherosclerosis related to resistance of LDL to oxidation? J. Clin. Invest. 94:1994;155-164.
6. Nagano Y., Nakamura T., Matsuzawa Y., Cho M., Ueda Y., Kita T. Probucol and atherosclerosis in the Watanabe heritable hyperlipidemic rabbit - long-term antiatherogenic effect and effects on established plaques. Atherosclerosis. 92:1992;131-140.
7. Carew T.E., Schwenke D.C., Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc. Natl. Acad. Sci. USA. 84:1987;7725-7729.
8. Kita T., Nagano Y., Yokode M., Ishii K., Kume N., Ooshima A., Yoshida H., Kaway C. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc. Natl. Acad. Sci. USA. 84:1987;5928-5931.
9. Feuerstein G.Z., Ruffolo R.R.J. Carvedilol a novel multiple action antihypertensive agent with antioxidant activity and potential for myocardial and vascular protection. Eur. Heart. J. 16:1995;38-42.
10. Yue T.-L., Cheng H., Lysko P.G., McKenna P.J., Feuerstein R., Gu J., Lysko K.A., Davis L.L., Feuerstein G.Z. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J. Pharmacol. Exp. Ther. 263(1):1992;92-98.
11. Ma X.-L., Yue T.-L., Lopez B.L., Barone F.C., Christopher T.A., Ruffolo R.R., Feuerstein G.Z. Carvedilol, a new beta adrenoreceptor blocker and free radical scavenger, attenuates myocardial ischemia-reperfusion injury in hypercholesterolemic rabbits. J. Pharmacol. Exp. Ther. 277:1996;128-136.
12. Ohlstein E.H., Douglas S.A., Sung C.P., Yue T.-L., Louden C., Arleth A., Poste G., Ruffolo R.R. Jr., Feuerstein G.Z. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration and neointimal formation following vascular injury. Proc. Natl. Acad. Sci. USA. 90:1993;6189-6193.
13. Booth R.F.G., Martin J.F., Honey A.C., Hassall D.G., Beesley J.E., Moncada S. Rapid development of atherosclerotic lesions in the rabbit carotid artery induced by perivascular manipulation. Atherosclerosis. 76:1989;257-268.
14. Soma M.R., Donetti E., Parolini C., Mazzini G., Ferrari C., Fumagalli R., Paoletti R. HMG CoA reductase inhibitors: in vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscl. Thromb. 13:1993;571-578.
15. Soma M.R., Donetti E., Parolini C., Sirtori C.R., Fumagalli R., Franceschini G. Recombinant apolipoprotein A-IMilano dimer inhibits carotid intimal thickening induced by perivascular manipulation in rabbits. Circ. Res. 76(3):1995;405-411.
16. Heinecke J.W., Rosen H., Suzuki L., Chait A. The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J. Biol. Chem. 262:1987;10098-10103.
17. Catapano A.L., Maggi F.M., Cicerano V. The antiatherosclerotic effect of anipamil in cholesterol-fed rabbits. Ann. NY. Acad. Sci. 522:1988;519-521.
18. Willette R.N., Sauermelch C.F., Ruffolo R.R. Jr. Local cutaneous hemodynamic effects of carvedilol and labetalol in the anesthetized rat. Eur. J. Pharmacol. 176(2):1990;237-240.
19. Nichols A.J., Gellai M., Ruffolo R.R. Jr. Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol. Fund. Clin. Pharmacol. 5(1):1991;25-38.
20. Ruffolo R.R. Jr., Boyle D.A., Venuti R.P., Lukas M.A. Carvedilol (Kredex): a novel multiple action cardiovascular agent. Drugs. Today. 27:1991;465-492.
21. Ruffolo R.R. Jr., Gellai M., Hieble J.P., Willette R.N., Nichols A.J. The pharmacology of carvedilol. Eur. J. Clin. Pharmacol. 38(suppl. 2):1990;82-88.
22. Jackson C.L., Bush R.C., Bowyer D.E. Inhibitory effect of calcium antagonists on balloon catheter-induced arterial smooth muscle cell proliferation and lesion size. Atherosclerosis. 69:1988;115-122.
23. Kauffman R.F., Bean J.S., Zimmermann K.M., Brown R.F., Steinberg M.I. Losartan, a nonpeptide angiotensin-II (ANG-II) receptor antagonist, inhibits neointima formation following balloon injury to rat carotid arteries. Life. Sci. 49:1991;223-228.
24. Fingerle J., Sanders K.H., Fotev Z. Alpha 1-receptor antagonists urapidil and prazosin inhibit neointima formation in rat carotid artery induced by balloon catheter injury. Basic. Res. Cardiol. 86(suppl. 1):1991;75-81.
25. Soma M.R., Donetti E., Parolini C., Barberi L., Paoletti R., Fumagalli R., Catapano A.L. Effect of lacidipine on the carotid intimal hyperplasia induced by cuff injury. J. Cardiovasc. Pharmacol. 23(suppl. 5):1994;71-74.
26. Soma M.R., Donetti E., Seregni R., Barberi L., Fumagalli R., Paoletti R., Catapano A.L. Effect of lacidipine on fatty and proliferative lesions induced in hypercholesterolemic rabbits. Br. J. Pharmacol. 118:1996;215-219.